Understand the source comparison
DSIP Epithalon Stack Protocol: Research Comparison Table
Standard Research Protocol 100–200 mcg subcutaneous, 30–60 min before sleep, 5–7 nights/week 1–2 mg subcutaneous daily, any consistent time DSIP: 4–6 weeks continuous; Epithalon: 10–20 days on, 4–6 months off Best for balanced longevity and recovery research w
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Standard Research Protocol
- 100–200 mcg subcutaneous, 30–60 min before sleep, 5–7 nights/week
- 1–2 mg subcutaneous daily, any consistent time
- DSIP: 4–6 weeks continuous; Epithalon: 10–20 days on, 4–6 months off
- Best for balanced longevity and recovery research with established dosing precedent
- Intensive Epithalon Cycle
- 100 mcg subcutaneous nightly
- 2 mg subcutaneous daily for 20 consecutive days
- Epithalon: 20 days on, 6 months off; DSIP: ongoing
- Maximizes telomerase activation window but requires strict adherence and extended off-cycle
- Sleep-Focused Protocol
- 200 mcg subcutaneous nightly, strict circadian timing
- 1 mg subcutaneous daily for 10 days
- DSIP: 6 weeks on, 2 weeks off; Epithalon: 10 days on, 4 months off
- Prioritizes immediate sleep architecture improvements with shorter Epithalon exposure
- Conservative Longevity Protocol
- 100 mcg subcutaneous 5 nights/week
- 1 mg subcutaneous every other day for 20 days total
- DSIP: continuous; Epithalon: 20 days on (over 40 calendar days), 6 months off
- Reduces injection frequency and total peptide load while maintaining chronic effects